Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Stock Performance

NASDAQ ONCT opened at $0.53 on Friday. The firm has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The business’s 50-day moving average price is $0.53 and its two-hundred day moving average price is $0.77. Oncternal Therapeutics has a 12 month low of $0.53 and a 12 month high of $9.88.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.